Blood Biomarkers for Alzheimer's Disease in Down Syndrome

被引：23

作者：

Montoliu-Gaya, Laia ^{[1
]}

Strydom, Andre ^{[2
,3
,4
]}

Blennow, Kaj ^{[1
,5
]}

Zetterberg, Henrik ^{[1
,5
,6
,7
,8
]}

Ashton, Nicholas James ^{[1
,9
,10
,11
]}

机构：

[1] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, S-43141 Molndal, Sweden

[2] Kings Coll London, Inst Psychiat, Dept Forens & Neurodev Sci, London WC2R 2LS, England

[3] South London & Maudsley NHS Fdn Trust, London SE5 8AZ, England

[4] London Syndrome Consortium LonDowns, London, England

[5] Sahlgrens Univ Hosp, Clin Neurochem Lab, S-41345 Molndal, Sweden

[6] UCL, Dept Neurodegenerat Dis, Queen Sq Inst Neurol, London WC1N 3BG, England

[7] UCL, UK Dementia Res Inst, London WC1E 6BT, England

[8] Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China

[9] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden

[10] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Dept Old Age Psychiat, London SE5 9RT, England

[11] Maudsley NHS Fdn, NIHR Biomed Res Ctr Mental Hlth, Biomed Res Unit Dementia South London, London SE5 8AF, England

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 16期

基金：

瑞典研究理事会; 英国医学研究理事会; 欧洲研究理事会; 美国国家卫生研究院;

关键词：

biomarkers; Down syndrome; Alzheimer's disease; blood; cerebrospinal fluid; positron emission tomography; PLASMA AMYLOID-BETA; NEUROFILAMENT LIGHT; CEREBROSPINAL-FLUID; INFLAMMATORY CYTOKINES; SYNDROME INDIVIDUALS; PROTEIN-1-42; LEVELS; OXIDATIVE STRESS; NUCLEUS BASALIS; AGE-DEPENDENCE; DEMENTIA;

D O I：

10.3390/jcm10163639

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Epidemiological evidence suggests that by the age of 40 years, all individuals with Down syndrome (DS) have Alzheimer's disease (AD) neuropathology. Clinical diagnosis of dementia by cognitive assessment is complex in these patients due to the pre-existing and varying intellectual disability, which may mask subtle declines in cognitive functioning. Cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers, although accurate, are expensive, invasive, and particularly challenging in such a vulnerable population. The advances in ultra-sensitive detection methods have highlighted blood biomarkers as a valuable and realistic tool for AD diagnosis. Studies with DS patients have proven the potential blood-based biomarkers for sporadic AD (amyloid-beta, tau, phosphorylated tau, and neurofilament light chain) to be useful in this population. In addition, biomarkers related to other pathologies that could aggravate dementia progression-such as inflammatory dysregulation, energetic imbalance, or oxidative stress-have been explored. This review serves to provide a brief overview of the main findings from the limited neuroimaging and CSF studies, outline the current state of blood biomarkers to diagnose AD in patients with DS, discuss possible past limitations of the research, and suggest considerations for developing and validating blood-based biomarkers in the future.

引用

页数：21

共 133 条

[21] Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline [J].

Cole, James H. ;

Annus, Tiina ;

Wilson, Liam R. ;

Remtulla, Ridhaa ;

Hong, Young T. ;

Fryer, Tim D. ;

Acosta-Cabronero, Julio ;

Cardenas-Blanco, Arturo ;

Smith, Robert ;

Menon, David K. ;

Zaman, Shahid H. ;

Nestor, Peter J. ;

Holland, Anthony J. .

NEUROBIOLOGY OF AGING, 2017, 56 :41-49

[22] Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome [J].

Coppus, Antonia M. W. ;

Schuur, Maaike ;

Vergeer, Jeanet ;

Janssens, A. Cecile J. W. ;

Oostra, Ben A. ;

Verbeek, Marcel M. ;

van Duijn, Cornelia M. .

NEUROBIOLOGY OF AGING, 2012, 33 (09) :1988-1994

[23]

Corsi MM, 2006, NEUROENDOCRINOL LETT, V27, P773

[24] Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease [J].

Coskun, Pinar ;

Helguera, Pablo ;

Nemati, Zahra ;

Bohannan, Ryan C. ;

Thomas, Jean ;

Schriner, Samuel E. ;

Argueta, Jocelyn ;

Doran, Eric ;

Wallace, Douglas C. ;

Lott, Ira T. ;

Busciglio, Jorge .

JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (02) :737-748

[25]

Cuello AC, 1996, PROG BRAIN RES, V109, P347

[26] The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome [J].

Davidson, Yvonne S. ;

Robinson, Andrew ;

Prasher, Vee P. ;

Mann, David M. A. .

ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 :56

[27]

Dekker Alain D, 2017, Alzheimers Dement (Amst), V8, P1, DOI 10.1016/j.dadm.2017.02.006

[28] Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome [J].

Dekker, Alain D. ;

Coppus, Antonia M. W. ;

Vermeiren, Yannick ;

Aerts, Tony ;

van Duijn, Cornelia M. ;

Kremer, Berry P. ;

Naude, Pieter J. W. ;

Van Dam, Debby ;

De Deyn, Peter P. .

JOURNAL OF ALZHEIMERS DISEASE, 2015, 43 (03) :871-891

[29] Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders [J].

Delaby, C. ;

Alcolea, D. ;

Carmona-Iragui, M. ;

Illan-Gala, I. ;

Morenas-Rodriguez, E. ;

Barroeta, I ;

Altuna, M. ;

Estelles, T. ;

Santos-Santos, M. ;

Turon-Sans, J. ;

Munoz, L. ;

Ribosa-Nogue, R. ;

Sala-Matavera, I ;

Sanchez-Saudinos, B. ;

Subirana, A. ;

Videla, L. ;

Benejam, B. ;

Sirisi, S. ;

Lehmann, S. ;

Belbin, O. ;

Clarimon, J. ;

Blesa, R. ;

Pagonabarraga, J. ;

Rojas-Garcia, R. ;

Fortea, J. ;

Lleo, A. .

SCIENTIFIC REPORTS, 2020, 10 (01)

[30] Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP [J].

Doran, Eric ;

Keator, David ;

Head, Elizabeth ;

Phelan, Michael J. ;

Kim, Ron ;

Totoiu, Minodora ;

Barrio, Jorge R. ;

Small, Gary W. ;

Potkin, Steven G. ;

Lott, Ira T. .

JOURNAL OF ALZHEIMERS DISEASE, 2017, 56 (02) :459-470

← 1 2 3 4 5 6 7 8 9 10 →